The proposed research is focused on increasing our understanding of the genetic causes of different types of muscular dystrophy. Goals of the research include the identification of causative genes, definition of the range of gene mutations, and the histological and clinical consequences of the gene/protein defects. A strength of the experimental approach is access to a large tissue bank of frozen muscle biopsies from patients. The availability of tissue within defined single gene defects allows comparative mRNA profiling, leading to disease-specific modeling of molecular pathophysiology. The proposed research leverages emerging DNA sequencing technologies to improve the diagnostics of the muscular dystrophies.
Aim 1 will develop emulsion PCR to separately amplify 841 exons corresponding to known muscular dystrophy genes, followed by highly parallel nextgen sequencing to identify causative gene mutations.
Aim 2 will take the mutation-positive biopsies identified in Aim 1, and conduct mRNA profiling to define disease-specific networks driving the muscle weakness in each gene-defined group.
In Aim 3, those patients testing negative for mutations in all 841 exons will be studied by whole-genome sequencing using Illumina and/or Pacific Biosciences methods. We anticipate the identification of multiple new genes causing muscular dystrophy, and this will inform diagnosis, enable experimental therapeutics, and increase knowledge of molecular pathogenesis. Integrated into these laboratory-based human research studies is design and implementation of novel bioinformatics and biostatistical approaches to analyses of genome-wide datasets, though collaboration with Dr. Yue Wang's group at Virginia Polytechnical University.
The proposed research develops new methods for enabling molecular diagnosis of the many types of muscular dystrophy. The proposed research will also identify novel genetic causes of muscular dystrophy, and increase the understanding of the molecular events leading to muscle weakness and disability.
|Punetha, Jaya; Kesari, Akanchha; Hoffman, Eric P et al. (2017) Novel Col12A1 variant expands the clinical picture of congenital myopathies with extracellular matrix defects. Muscle Nerve 55:277-281|
|Perovanovic, Jelena; Dell'Orso, Stefania; Gnochi, Viola F et al. (2016) Laminopathies disrupt epigenomic developmental programs and cell fate. Sci Transl Med 8:335ra58|
|Chen, Xi; Jung, Jin-Gyoung; Shajahan-Haq, Ayesha N et al. (2016) ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Res 44:e65|
|Punetha, Jaya; Mansoor, Simin; Bertorini, Tulio E et al. (2016) Somatic mosaicism due to a reversion variant causing hemi-atrophy: a novel variant of dystrophinopathy. Eur J Hum Genet 24:1511-4|
|Willkomm, Lena; Heredia, Raul; Hoffmann, Katrin et al. (2016) Homozygous mutation in Atlastin GTPase 1 causes recessive hereditary spastic paraplegia. J Hum Genet 61:571-3|
|O'Grady, Gina L; Lek, Monkol; Lamande, Shireen R et al. (2016) Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. Ann Neurol 80:101-11|
|Punetha, Jaya; Kesari, Akanchha; Uapinyoying, Prech et al. (2016) Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases. J Neuromuscul Dis 3:209-225|
|Wang, Niya; Hoffman, Eric P; Chen, Lulu et al. (2016) Mathematical modelling of transcriptional heterogeneity identifies novel markers and subpopulations in complex tissues. Sci Rep 6:18909|
|Many, Gina M; Yokosaki, Yasuyuki; Uaesoontrachoon, Kitipong et al. (2016) OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages. Exp Physiol 101:1285-1300|
|Rosenberg, Amy S; Puig, Montserrat; Nagaraju, Kanneboyina et al. (2015) Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med 7:299rv4|
Showing the most recent 10 out of 94 publications